Topics

Daiichi Sankyo Europe, Esperion pen potential $900mm cardio deal

15:40 EDT 3 Oct 2019 | Elsevier Business Intelligence

Esperion Therapeutics Inc. licensed Daiichi Sankyo Europe GmbH exclusive rights to commercialize its oral cholesterol drug be...

Original Article: Daiichi Sankyo Europe, Esperion pen potential $900mm cardio deal

NEXT ARTICLE

More From BioPortfolio on "Daiichi Sankyo Europe, Esperion pen potential $900mm cardio deal"

Quick Search

Relevant Topics

Cholesterol
Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...